GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: example 34 [WO2020254946] | PF-07248144 | PF07248144
Compound class:
Synthetic organic
Comment: Prifetrastat (PF-07248144) is a histone lysine acetyltransferase KAT6A/B inhibitor [2,4]. Inhibition of histone acetyltransferases KAT6A/B induces senescence and arrests tumour growth [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, Nguyen N, Wichmann J, McRae HM, Yang Y et al.. (2018)
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature, 560 (7717): 253-257. [PMID:30069049] |
2. Bozikis YEB, Brodsky O, Camerino MA, Greasley SE, Hoffman RL, Kumpf RA, Kung PP, Richardson PF, Stupple PA, Sutton SC. (2020)
Benzisoxazole sulfonamide derivatives. Patent number: WO2020254946A1. Assignee: Pfizer Inc., Ctxt Pty Ltd. Priority date: 16/06/2020. Publication date: 24/12/2020. |
3. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM et al.. (2024)
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med, 30 (8): 2371. [PMID:38914862] |
4. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM et al.. (2024)
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med, 30 (8): 2242-2250. [PMID:38824244] |